HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Foster, D. R. Articles by Amidon, G. L. Search for Related Content PubMed PubMed Citation Articles by Foster, D. R. Articles by Amidon, G. L. Social Bookmarking                         What's this?

Lack of Interaction Between the Peptidomimetic Substrates Captopril and Cephradine

From Department of Pharmacy Practice, Purdue University, School of Pharmacy and Pharmaceutical Sciences, Indianapolis, IN (Dr Foster), Shiyin Yee Inc., Cupertino, CA (Dr Yee), College of Pharmacy, University of Michigan, and Department of Pharmacy Services, University Hospital, Ann Arbor, MI (Dr Bleske, Dr Carver, Dr Welage), Department of Internal Medicine, Medical School, University of Michigan, Ann Arbor, MI (Dr Shea), Pfizer, Inc., New London, CT (Dr Menon), and College of Pharmacy, University of Michigan, Ann Arbor, MI (Dr Ramachandran, Dr Amidon).

Intestinal peptide transporters, including hPEPT1, facilitate the absorption of cephalosporins and angiotensin-converting enzyme inhibitors, and have been investigated as a means to improve oral drug absorption. Renal peptide transporters including hPEPT2, may also facilitate renal reabsorption of such compounds. In vitro and animal studies suggest that co-administration of peptidomimetic compounds may alter oral pharmacokinetics, although this has not been well studied in humans. The purpose of this study was to determine whether co-administration of the hPEPT substrates captopril and cephradine alters the oral pharmacokinetics of either agent. Nine healthy male volunteers received a single oral 25-mg dose of captopril, a single oral 500-mg dose of cephradine, or concurrent ingestion of captopril and cephradine in a cross-over manner. Venous blood samples were taken and captopril and cephradine pharmacokinetics were determined using noncompartmental analyses. No significant differences were observed in captopril or cephradine pharmacokinetics when administered together as compared to each agent alone (a marginal decrease in C_max was observed for both captopril and cephradine during co-administration [5–15%]; however, differences were not statistically significant). The results of our study suggest that hPEPT1 and hPEPT2 are unlikely to contribute to clinically important drug interactions in humans.

Key Words: Cephalosporin • ACE-inhibitor • peptide transport • drug interaction • hPEPT1

Address for reprints: Gordon L. Amidon, PhD, Department of Pharmaceutical Sciences, The University of Michigan College of Pharmacy, 428 Church Street, Ann Arbor, MI, 48109-1065. E-mail: glamidon{at}umich.edu.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?